By Bhanvi Satija LONDON, April 29 (Reuters) - Strong first-quarter results under new GSK CEO Luke Miels on Wednesday failed to impress investors, who raised concerns that the British drugmaker's ...

GSK (LSE:GSK) and Alector have discontinued their phase 2 trial of an Alzheimer's drug candidate after the study did not meet efficacy goals. The decision effectively ends a high profile collaboration ...

GSK has signed a new three-year agreement with Protas that aims to streamline trials across several core therapeutic areas.

GSK stock looks more attractive after a small pullback, supported by higher dividends, share buybacks, solid Q1 2026 results, and deal strength—read now.

GSK plc (NYSE:GSK) ranks among the best low-risk investments in May 2026. GSK plc (NYSE:GSK) stated on April 15 that it had completed the acquisition of 35Pharma Inc., a private clinical-stage ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

GSK has disclosed a series of routine share dealings by senior executives under its Share Reward Plan, with ordinary shares acquired on 12 May 2026 on the London Stock Exchange. Participants include ...

May 11 (Reuters) - Britain's GSK said on Monday it signed a deal with Hong Kong-listed Sino Biopharmaceutical to expand its presence in the growing mainland China market and sell its experimental ...

You’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine. Sign up to get it delivered in your inbox every ...

The pharmaceutical giant said core operating profit for the first quarter was £2.65 billion compared with £2.53 billion for the same period a year earlier.

Twelve companies are set to turn ex-dividend on Friday, with payouts totaling over Rs 250. Investors must own shares by ...